SOURCE: Imagin Medical Inc.

Imagin Medical Inc.

April 12, 2016 09:15 ET

Imagin Announces i/Blue Product Development Program Moves to University of Rochester Laboratory for Laser Energetics

Imagin Medical Is the Developer of the Ultrasensitive i/Blue Imaging System That Will Establish a New Standard of Care for Urologists in Detecting Bladder Cancer Through Endoscopes

VANCOUVER, BC and BOSTON, MA--(Marketwired - April 12, 2016) -  Imagin Medical (CSE: IME) (the "Company") announced today that Dr. Stavros Demos, the inventor of the i/Blue Imaging System, has accepted the position of "Senior Scientist and Group Leader of the Optical Materials Group" at the University of Rochester Laboratory for Laser Energetics (LLE) in New York. LLE has a world class reputation for developing successful laser and optical technologies and supporting a variety of US Government missions. Going forward, Imagin Medical will utilize LLE's resources to continue development of its ultrasensitive cancer imaging technology.

"Being able to work with such an extraordinary pool of scientists and engineers in their state-of-the-art facility focused exclusively on Imagin's field of interest is a great opportunity for us," said Jim Hutchens, Imagin President and CEO. "Their expertise and success with laser and optical technology applications will help drive our development program more rapidly and may result in additional intellectual property."

LLE was established in 1970 and has become an internationally known resource for research and education in science and technology. A pioneer in university/industry collaborations, LLE employs over 300 engineers and scientists with a recognized expertise in laser, optics and the interaction of light with matter.

Dr. Demos will lead the effort at University of Rochester and LLE to build on Imagin's initial prototype and continue to refine the product's design, requalifying the system's optical model, components and advanced light sensors, and help create the controls needed for optimized operation and patient safety. These next generation (beta) products will be used for clinical trials, regulatory submission and eventual commercial distribution.

During Imagin's first development meeting held at LLE in Rochester, NY, Dr. Demos commented, "Working at Lawrence Livermore National Laboratory (LLNL) in California for twelve years was an invaluable experience while focusing on contributing to LLNL mission goals. Now, at LLE, I'm joining former colleagues and collaborators along with a world class team of scientists and Medical school and hospital that can be a great asset in the efforts to continuing the development of Imagin's i/Blue Imaging System."

About Imagin Medical 
Imagin Medical is developing imaging solutions for the early detection of cancer. The Company is focused on advanced medical imaging to radically improve the way physicians detect cancer through the use of endoscopes. Imagin's initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate.

Developed by Dr. Stavros Demos, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors.

Learn more at


Jim Hutchens,

President & CEO

CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Image Available:

Contact Information

  • For further information, contact:
    Bill Galine
    Investor Relations
    Telephone: (775) 737-3292